Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection
详细信息    查看全文
  • 作者：Milan Raska (1) (2)
    Lydie Czernekova (1)
    Zina Moldoveanu (2)
    Katerina Zachova (1)
    Matt C Elliott (2)
    Zdenek Novak (8)
    Stacy Hall (2)
    Michael Hoelscher (3)
    Leonard Maboko (4)
    Rhubell Brown (2)
    Phillip D Smith (5) (6)
    Jiri Mestecky (2) (5) (7)
    Jan Novak (2)

    1. Department of Immunology     ; Palacky University in Olomouc ; 77100 ; Olomouc ; Czech Republic
    2. Department of Microbiology     ; University of Alabama at Birmingham ; Birmingham ; AL ; 35294 ; USA
    8. Department of Surgery     ; University of Alabama at Birmingham ; Birmingham ; AL ; 35294 ; USA
    3. Department of Infectious Diseases & Tropical Medicine     ; Clinic of the University of Munich ; Munich ; Germany
    4. NIMR-Mbeya Medical Research Programme     ; Mbeya ; Tanzania
    5. Department of Medicine     ; University of Alabama at Birmingham ; Birmingham ; AL ; 35294 ; USA
    6. VA Medical Center     ; Birmingham ; AL ; 35205 ; USA
    7. Institute of Microbiology and Immunology     ; First Faculty of Medicine ; Charles University ; 12108 ; Prague ; Czech Republic
  • 关键词：gp120 glycosylation ; Glycan ; specific antibody ; Deglycosylation resistance ; Neutralization inhibition
  • 刊名：AIDS Research and Therapy
  • 出版年：2014
  • 出版时间：December 2014
  • 年：2014
  • 卷：11
  • 期：1
  • 全文大小：1,247 KB
  • 参考文献：1. Kwong, PD, Wyatt, R, Robinson, J, Sweet, RW, Sodroski, J, Hendrickson, WA (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: pp. 648-659 CrossRef
    2. Wyatt, R, Kwong, PD, Desjardins, E, Sweet, RW, Robinson, J, Hendrickson, WA, Sodroski, JG (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: pp. 705-711 CrossRef
    3. Pantophlet, R, Burton, DR (2006) gp120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: pp. 739-769 CrossRef
    4. Wei, X, Decker, JM, Wang, S, Hui, H, Kappes, JC, Wu, X, Salazar-Gonzalez, JF, Salazar, MG, Kilby, JM, Saag, MS, Komarova, NL, Nowak, MA, Hahn, BH, Kwong, PD, Shaw, GM (2003) Antibody neutralization and escape by HIV-1. Nature 422: pp. 307-312 CrossRef
    5. Arthos, J, Cicala, C, Martinelli, E, Macleod, K, Van Ryk, D, Wei, D, Xiao, Z, Veenstra, TD, Conrad, TP, Lempicki, RA, McLaughlin, S, Pascuccio, M, Gopaul, R, McNally, J, Cruz, CC, Censoplano, N, Chung, E, Reitano, KN, Kottilil, S, Goode, DJ, Fauci, AS (2008) HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9: pp. 301-309 CrossRef
    6. Cicala, C, Martinelli, E, McNally, JP, Goode, DJ, Gopaul, R, Hiatt, J, Jelicic, K, Kottilil, S, Macleod, K, O鈥橲hea, A, Patel, N, Van Ryk, D, Wei, D, Pascuccio, M, Yi, L, McKinnon, L, Izulla, P, Kimani, J, Kaul, R, Fauci, AS, Arthos, J (2009) The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 106: pp. 20877-20882 CrossRef
    7. Hioe, CE, Bastiani, L, Hildreth, JE, Zolla-Pazner, S (1998) Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization. AIDS Res Hum Retroviruses 14: pp. S247-S254
    8. Hioe, CE, Hildreth, JE, Zolla-Pazner, S (1999) Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1. AIDS Res Hum Retroviruses 15: pp. 523-531 CrossRef
    9. Simek, MD, Rida, W, Priddy, FH, Pung, P, Carrow, E, Laufer, DS, Lehrman, JK, Boaz, M, Tarragona-Fiol, T, Miiro, G, Birungi, J, Pozniak, A, McPhee, DA, Manigart, O, Karita, E, Inwoley, A, Jaoko, W, DeHovitz, J, Bekker, L-G, Pitisuttithum, P, Paris, R, Walker, LM, Poignard, P, Wrin, T, Fast, PE, Burton, DR, Koff, WC (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83: pp. 7337-7348 CrossRef
    10. Doria-Rose, NA, Klein, RM, Manion, MM, O鈥橠ell, S, Phogat, A, Chakrabarti, B, Hallahan, CW, Migueles, SA, Wrammert, J, Ahmed, R, Nason, M, Wyatt, RT, Mascola, JR, Connors, M (2009) Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83: pp. 188-199 CrossRef
    11. Walker, LM, Simek, MD, Priddy, F, Gach, JS, Wagner, D, Zwick, MB, Phogat, SK, Poignard, P, Burton, DR (2010) A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 6: pp. e1001028 CrossRef
    12. Stamatatos, L, Morris, L, Burton, DR, Mascola, JR (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 15: pp. 866-870
    13. Fauci, AS (2008) 25聽years of HIV. Nature 453: pp. 289-290 CrossRef
    14. Balzarini, J (2005) Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV. Lancet Infect Dis 5: pp. 726-731 CrossRef
    15. Letvin, NL, Rao, SS, Dang, V, Buzby, AP, Korioth-Schmitz, B, Dombagoda, D, Parvani, JG, Clarke, RH, Bar, L, Carlson, KR, Kozlowski, PA, Hirsch, VM, Mascola, JR, Nabel, GJ (2007) No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys. J Virol 81: pp. 12368-12374 CrossRef
    16. Robinson, HL (2007) HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 82: pp. 686-693 CrossRef
    17. Zhu, X, Borchers, C, Bienstock, RJ, Tomer, KB (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39: pp. 11194-11204 CrossRef
    18. Go, EP, Chang, Q, Liao, HX, Sutherland, LL, Alam, SM, Haynes, BF, Desaire, H (2009) Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J Proteome Res 8: pp. 4231-4242 CrossRef
    19. Go, EP, Hewawasam, G, Liao, HX, Chen, H, Ping, LH, Anderson, JA, Hua, DC, Haynes, BF, Desaire, H (2011) Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 85: pp. 8270-8284 CrossRef
    20. Raska, M, Novak, J (2010) Involvement of envelope-glycoprotein glycans in HIV-1 biology and infection. Arch Immunol Ther Exp (Warsz) 58: pp. 191-208 CrossRef
    21. Raska, M, Takahashi, K, Czernekova, L, Zachova, K, Hall, S, Moldoveanu, Z, Elliot, MC, Wilson, L, Brown, R, Jancova, D, Barnes, S, Vrbkova, J, Tomana, M, Smith, PD, Mestecky, J, Renfrow, MB, Novak, J (2010) Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 285: pp. 20860-20869 CrossRef
    22. Mizuochi, T, Matthews, TJ, Kato, M, Hamako, J, Titani, K, Solomon, J, Feizi, T (1990) Diversity of oligosaccharide structures on the envelope glycoprotein gp120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J Biol Chem 265: pp. 8519-8524
    23. Mizuochi, T, Spellman, MW, Larkin, M, Solomon, J, Basa, LJ, Feizi, T (1988) Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. Biomed Chromatogr 2: pp. 260-270 CrossRef
    24. Mizuochi, T, Spellman, MW, Larkin, M, Solomon, J, Basa, LJ, Feizi, T (1988) Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem J 254: pp. 599-603
    25. Reitter, JN, Means, RE, Desrosiers, RC (1998) A role for carbohydrates in immune evasion in AIDS. Nat Med 4: pp. 679-684 CrossRef
    26. Reitter, JN, Desrosiers, RC (1998) Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. J Virol 72: pp. 5399-5407
    27. Ho, YS, Abecasis, AB, Theys, K, Deforche, K, Dwyer, DE, Charleston, M, Vandamme, AM, Saksena, NK (2008) HIV-1 gp120 N-linked glycosylation differs between plasma and leukocyte compartments. Virol J 5: pp. 14 CrossRef
    28. Go, EP, Irungu, J, Zhang, Y, Dalpathado, DS, Liao, HX, Sutherland, LL, Alam, SM, Haynes, BF, Desaire, H (2008) Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes鈥?accessibility. J Proteome Res 7: pp. 1660-1674 CrossRef
    29. Clapham, PR, McKnight, A (2001) HIV-1 receptors and cell tropism. Br Med Bull 58: pp. 43-59 CrossRef
    30. Cicala, C, Arthos, J, Fauci, AS (2011) HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med 9: pp. S2 CrossRef
    31. Decker, JM, Bibollet-Ruche, F, Wei, X, Wang, S, Levy, DN, Wang, W, Delaporte, E, Peeters, M, Derdeyn, CA, Allen, S, Hunter, E, Saag, MS, Hoxie, JA, Hahn, BH, Kwong, PD, Robinson, JE, Shaw, GM (2005) Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201: pp. 1407-1419 CrossRef
    32. Salazar-Gonzalez, JF, Bailes, E, Pham, KT, Salazar, MG, Guffey, MB, Keele, BF, Derdeyn, CA, Farmer, P, Hunter, E, Allen, S, Manigart, O, Mulenga, J, Anderson, JA, Swanstrom, R, Haynes, BF, Athreya, GS, Korber, BT, Sharp, PM, Shaw, GM, Hahn, BH (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 82: pp. 3952-3970 CrossRef
    33. Pollakis, G, Kang, S, Kliphuis, A, Chalaby, MI, Goudsmit, J, Paxton, WA (2001) N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 276: pp. 13433-13441 CrossRef
    34. McCaffrey, RA, Saunders, C, Hensel, M, Stamatatos, L (2004) N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 78: pp. 3279-3295 CrossRef
    35. Clevestig, P, Pramanik, L, Leitner, T, Ehrnst, A (2006) CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. J Gen Virol 87: pp. 607-612 CrossRef
    36. Wolk, T, Schreiber, M (2006) N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med Microbiol Immunol 195: pp. 165-172 CrossRef
    37. Huang, X, Jin, W, Hu, K, Luo, S, Du, T, Griffin, GE, Shattock, RJ, Hu, Q (2012) Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 423: pp. 97-106 CrossRef
    38. Rerks-Ngarm, S, Pitisuttithum, P, Nitayaphan, S, Kaewkungwal, J, Chiu, J, Paris, R, Premsri, N, Namwat, C, de Souza, M, Adams, E, Benenson, M, Gurunathan, S, Tartaglia, J, McNeil, JG, Francis, DP, Stablein, D, Birx, DL, Chunsuttiwat, S, Khamboonruang, C, Thongcharoen, P, Robb, ML, Michael, NL, Kunasol, P, Kim, JH (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: pp. 2209-2220 CrossRef
    39. Haynes, BF, Gilbert, PB, McElrath, MJ, Zolla-Pazner, S, Tomaras, GD, Alam, SM, Evans, DT, Montefiori, DC, Karnasuta, C, Sutthent, R, Liao, HX, DeVico, AL, Lewis, GK, Williams, C, Pinter, A, Fong, Y, Janes, H, DeCamp, A, Huang, Y, Rao, M, Billings, E, Karasavvas, N, Robb, ML, Ngauy, V, de Souza, MS, Paris, R, Ferrari, G, Bailer, RT, Soderberg, KA, Andrews, C (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: pp. 1275-1286 CrossRef
    40. Doores, KJ, Burton, DR (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84: pp. 10510-10521 CrossRef
    41. Walker, LM, Huber, M, Doores, KJ, Falkowska, E, Pejchal, R, Julien, JP, Wang, SK, Ramos, A, Chan-Hui, PY, Moyle, M, Mitcham, JL, Hammond, PW, Olsen, OA, Phung, P, Fling, S, Wong, CH, Phogat, S, Wrin, T, Simek, MD, Koff, WC, Wilson, IA, Burton, DR, Poignard, P (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: pp. 466-470 CrossRef
    42. Kwong, PD, Mascola, JR, Nabel, GJ (2012) The changing face of HIV vaccine research. Journal of the International Aids Society 15: pp. 17407 CrossRef
    43. Platt, EJ, Gomes, MM, Kabat, D (2012) Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry. Proc Natl Acad Sci U S A 109: pp. 7829-7834 CrossRef
    44. Pejchal, R, Doores, KJ, Walker, LM, Khayat, R, Huang, PS, Wang, SK, Stanfield, RL, Julien, JP, Ramos, A, Crispin, M, Depetris, R, Katpally, U, Marozsan, A, Cupo, A, Maloveste, S, Liu, Y, McBride, R, Ito, Y, Sanders, RW, Ogohara, C, Paulson, JC, Feizi, T, Scanlan, CN, Wong, CH, Moore, JP, Olson, WC, Ward, AB, Poignard, P, Schief, WR, Burton, DR (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334: pp. 1097-1103 CrossRef
    45. Walker, LM, Phogat, SK, Chan-Hui, PY, Wagner, D, Phung, P, Goss, JL, Wrin, T, Simek, MD, Fling, S, Mitcham, JL, Lehrman, JK, Priddy, FH, Olsen, OA, Frey, SM, Hammond, PW, Kaminsky, S, Zamb, T, Moyle, M, Koff, WC, Poignard, P, Burton, DR (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: pp. 285-289 CrossRef
    46. Pejchal, R, Walker, LM, Stanfield, RL, Phogat, SK, Koff, WC, Poignard, P, Burton, DR, Wilson, IA (2010) Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107: pp. 11483-11488 CrossRef
    47. Julien, JP, Sok, D, Khayat, R, Lee, JH, Doores, KJ, Walker, LM, Ramos, A, Diwanji, DC, Pejchal, R, Cupo, A, Katpally, U, Depetris, RS, Stanfield, RL, McBride, R, Marozsan, AJ, Paulson, JC, Sanders, RW, Moore, JP, Burton, DR, Poignard, P, Ward, AB, Wilson, IA (2013) Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 9: pp. e1003342 CrossRef
    48. Calarese, DA, Scanlan, CN, Zwick, MB, Deechongkit, S, Mimura, Y, Kunert, R, Zhu, P, Wormald, MR, Stanfield, RL, Roux, KH, Kelly, JW, Rudd, PM, Dwek, RA, Katinger, H, Burton, DR, Wilson, IA (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: pp. 2065-2071 CrossRef
    49. Eggink, D, Melchers, M, Wuhrer, M, van Montfort, T, Dey, AK, Naaijkens, BA, David, KB, Le Douce, V, Deelder, AM, Kang, K, Olson, WC, Berkhout, B, Hokke, CH, Moore, JP, Sanders, RW (2010) Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 401: pp. 236-247 CrossRef
    50. Kong, L, Sheppard, NC, Stewart-Jones, GB, Robson, CL, Chen, H, Xu, X, Krashias, G, Bonomelli, C, Scanlan, CN, Kwong, PD, Jeffs, SA, Jones, IM, Sattentau, QJ (2010) Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J Mol Biol 403: pp. 131-147 CrossRef
    51. Gorny, MK, Xu, JY, Gianakakos, V, Karwowska, S, Williams, C, Sheppard, HW, Hanson, CV, Zolla-Pazner, S (1991) Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A 88: pp. 3238-3242 CrossRef
    52. Pantophlet, R, Aguilar-Sino, RO, Wrin, T, Cavacini, LA, Burton, DR (2007) Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 364: pp. 441-453 CrossRef
    53. Gorny, MK, Conley, AJ, Karwowska, S, Buchbinder, A, Xu, JY, Emini, EA, Koenig, S, Zolla-Pazner, S (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 66: pp. 7538-7542
    54. Burton, DR, Barbas, CF, Persson, MA, Koenig, S, Chanock, RM, Lerner, RA (1991) A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A 88: pp. 10134-10137 CrossRef
    55. Pantophlet, R, Wang, M, Aguilar-Sino, RO, Burton, DR (2009) The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions. J Virol 83: pp. 1649-1659 CrossRef
    56. Bonomelli, C, Doores, KJ, Dunlop, DC, Thaney, V, Dwek, RA, Burton, DR, Crispin, M, Scanlan, CN (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6: pp. e23521 CrossRef
    57. Julien, JP, Lee, PS, Wilson, IA (2012) Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev 250: pp. 180-198 CrossRef
    58. Derdeyn, CA, Decker, JM, Bibollet-Ruche, F, Mokili, JL, Muldoon, M, Denham, SA, Heil, ML, Kasolo, F, Musonda, R, Hahn, BH, Shaw, GM, Korber, BT, Allen, S, Hunter, E (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: pp. 2019-2022 CrossRef
    59. Li, H, Chien, PC, Tuen, M, Visciano, ML, Cohen, S, Blais, S, Xu, CF, Zhang, HT, Hioe, CE (2008) Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes. J Immunol 180: pp. 4011-4021 CrossRef
    60. Kothe, DL, Decker, JM, Li, Y, Weng, Z, Bibollet-Ruche, F, Zammit, KP, Salazar, MG, Chen, Y, Salazar-Gonzalez, JF, Moldoveanu, Z, Mestecky, J, Gao, F, Haynes, BF, Shaw, GM, Muldoon, M, Korber, BT, Hahn, BH (2007) Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360: pp. 218-234 CrossRef
    61. Huang, X, Barchi, JJ, Lung, FD, Roller, PP, Nara, PL, Muschik, J, Garrity, RR (1997) Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135. Biochemistry 36: pp. 10846-10856 CrossRef
    62. Wain, LV, Bailes, E, Bibollet-Ruche, F, Decker, JM, Keele, BF, Van Heuverswyn, F, Li, Y, Takehisa, J, Ngole, EM, Shaw, GM, Peeters, M, Hahn, BH, Sharp, PM (2007) Adaptation of HIV-1 to its human host. Mol Biol Evol 24: pp. 1853-1860 CrossRef
    63. Reitz, MS, Hall, L, Robert-Guroff, M, Lautenberger, J, Hahn, BM, Shaw, GM, Kong, LI, Weiss, SH, Waters, D, Gallo, RC, Blattner, WA (1994) Viral variability and serum antibody response in a laboratory worker infected with HIV type 1 (HTLV type IIIB). AIDS Res Hum Retroviruses 10: pp. 1143-1155 CrossRef
    64. Rong, R, Gnanakaran, S, Decker, JM, Bibollet-Ruche, F, Taylor, J, Sfakianos, JN, Mokili, JL, Muldoon, M, Mulenga, J, Allen, S, Hahn, BH, Shaw, GM, Blackwell, JL, Korber, BT, Hunter, E, Derdeyn, CA (2007) Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 81: pp. 5658-5668 CrossRef
    65. Keele, BF, Giorgi, EE, Salazar-Gonzalez, JF, Decker, JM, Pham, KT, Salazar, MG, Sun, C, Grayson, T, Wang, S, Li, H, Wei, X, Jiang, C, Kirchherr, JL, Gao, F, Anderson, JA, Ping, LH, Swanstrom, R, Tomaras, GD, Blattner, WA, Goepfert, PA, Kilby, JM, Saag, MS, Delwart, EL, Busch, MP, Cohen, MS, Montefiori, DC, Haynes, BF, Gaschen, B, Athreya, GS, Lee, HY (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: pp. 7552-7557 CrossRef
    66. Burton, DR, Ahmed, R, Barouch, DH, Butera, ST, Crotty, S, Godzik, A, Kaufmann, DE, McElrath, MJ, Nussenzweig, MC, Pulendran, B, Scanlan, CN, Schief, WR, Silvestri, G, Streeck, H, Walker, BD, Walker, LM, Ward, AB, Wilson, IA, Wyatt, R (2012) A blueprint for HIV vaccine discovery. Cell Host Microbe 12: pp. 396-407 CrossRef
    67. Koff, WC (2012) HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 30: pp. 4310-4315 CrossRef
    68. Moore, PL, Gray, ES, Wibmer, CK, Bhiman, JN, Nonyane, M, Sheward, DJ, Hermanus, T, Bajimaya, S, Tumba, NL, Abrahams, MR, Lambson, BE, Ranchobe, N, Ping, L, Ngandu, N, Abdool Karim, Q, Abdool Karim, SS, Swanstrom, RI, Seaman, MS, Williamson, C, Morris, L (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18: pp. 1688-1692 CrossRef
    69. Wang, W, Nie, J, Prochnow, C, Truong, C, Jia, Z, Wang, S, Chen, XS, Wang, Y (2013) A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology 10: pp. 14 CrossRef
    70. Gorny, MK, Xu, JY, Karwowska, S, Buchbinder, A, Zolla-Pazner, S (1993) Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 150: pp. 635-643
    71. Bell, CH, Pantophlet, R, Schiefner, A, Cavacini, LA, Stanfield, RL, Burton, DR, Wilson, IA (2008) Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J Mol Biol 375: pp. 969-978 CrossRef
    72. Stanfield, RL, Gorny, MK, Williams, C, Zolla-Pazner, S, Wilson, IA (2004) Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 12: pp. 193-204 CrossRef
    73. Burke, V, Williams, C, Sukumaran, M, Kim, SS, Li, H, Wang, XH, Gorny, MK, Zolla-Pazner, S, Kong, XP (2009) Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure 17: pp. 1538-1546 CrossRef
    74. Moore, JP, Trkola, A, Korber, B, Boots, LJ, Kessler, JA, McCutchan, FE, Mascola, J, Ho, DD, Robinson, J, Conley, AJ (1995) A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol 69: pp. 122-130
    75. Scanlan, CN, Pantophlet, R, Wormald, MR, Saphire, EO, Calarese, D, Stanfield, R, Wilson, IA, Katinger, H, Dwek, RA, Burton, DR, Rudd, PM (2003) The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv Exp Med Biol 535: pp. 205-218 CrossRef
    76. Sanders, RW, Venturi, M, Schiffner, L, Kalyanaraman, R, Katinger, H, Lloyd, KO, Kwong, PD, Moore, JP (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76: pp. 7293-7305 CrossRef
    77. Mouquet, H, Scharf, L, Euler, Z, Liu, Y, Eden, C, Scheid, JF, Halper-Stromberg, A, Gnanapragasam, PN, Spencer, DI, Seaman, MS, Schuitemaker, H, Feizi, T, Nussenzweig, MC, Bjorkman, PJ (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 109: pp. E3268-E3277 CrossRef
    78. Pancera, M, Shahzad-Ul-Hussan, S, Doria-Rose, NA, McLellan, JS, Bailer, RT, Dai, K, Loesgen, S, Louder, MK, Staupe, RP, Yang, Y, Zhang, B, Parks, R, Eudailey, J, Lloyd, KE, Blinn, J, Alam, SM, Haynes, BF, Amin, MN, Wang, LX, Burton, DR, Koff, WC, Nabel, GJ, Mascola, JR, Bewley, CA, Kwong, PD (2013) Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 20: pp. 804-813 CrossRef
    79. Zhou, T, Xu, L, Dey, B, Hessell, AJ, Van Ryk, D, Xiang, SH, Yang, X, Zhang, MY, Zwick, MB, Arthos, J, Burton, DR, Dimitrov, DS, Sodroski, J, Wyatt, R, Nabel, GJ, Kwong, PD (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: pp. 732-737 CrossRef
    80. Wu, X, Zhou, T, O鈥橠ell, S, Wyatt, RT, Kwong, PD, Mascola, JR (2009) Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol 83: pp. 10892-10907 CrossRef
    81. Wu, X, Yang, Z-Y, Li, Y, Hogerkorp, C-M, Schief, WR, Seaman, MS, Zhou, T, Schmidt, SD, Wu, L, Xu, L, Longo, NS, McKee, K, O'Dell, S, Louder, MK, Wycuff, DL, Feng, Y, Nason, M, Doria-Rose, N, Connors, M, Kwong, PD, Roederer, M, Wyatt, RT, Nabel, GJ, Mascola, JR (2010) Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science 329: pp. 856-861 CrossRef
    82. Li, Y, O鈥橠ell, S, Walker, LM, Wu, X, Guenaga, J, Feng, Y, Schmidt, SD, McKee, K, Louder, MK, Ledgerwood, JE, Graham, BS, Haynes, BF, Burton, DR, Wyatt, RT, Mascola, JR (2011) Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol 85: pp. 8954-8967 CrossRef
    83. Doores, KJ, Fulton, Z, Huber, M, Wilson, IA, Burton, DR (2010) Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol 84: pp. 10690-10699 CrossRef
    84. Crooks, ET, Tong, T, Osawa, K, Binley, JM (2011) Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol 85: pp. 5825-5839 CrossRef
    85. Means, RE, Desrosiers, RC (2000) Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases. J Virol 74: pp. 11181-11190 CrossRef
    86. Raska, M, Moldoveanu, Z, Novak, J, Hel, Z, Novak, L, Bozja, J, Compans, RW, Yang, C, Mestecky, J (2008) Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses. Vaccine 26: pp. 1541-1551 CrossRef
    87. Li, Y, Luo, L, Rasool, N, Kang, CY (1993) Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J Virol 67: pp. 584-588
    88. Doores, KJ, Bonomelli, C, Harvey, DJ, Vasiljevic, S, Dwek, RA, Burton, DR, Crispin, M, Scanlan, CN (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 107: pp. 13800-13805 CrossRef
    89. Hemming, A, Gram, GJ, Bolmstedt, A, Losman, B, Hansen, JE, Ricksten, A, Olofsson, S (1996) Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies. Arch Virol 141: pp. 2139-2151 CrossRef
    90. Trkola, A, Purtscher, M, Muster, T, Ballaun, C, Buchacher, A, Sullivan, N, Srinivasan, K, Sodroski, J, Moore, JP, Katinger, H (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: pp. 1100-1108
    91. Doria-Rose, NA, Georgiev, I, O鈥橠ell, S, Chuang, GY, Staupe, RP, McLellan, JS, Gorman, J, Pancera, M, Bonsignori, M, Haynes, BF, Burton, DR, Koff, WC, Kwong, PD, Mascola, JR (2012) A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol 86: pp. 8319-8323 CrossRef
    92. Zhu, J, O鈥橠ell, S, Ofek, G, Pancera, M, Wu, X, Zhang, B, Zhang, Z, Mullikin, JC, Simek, M, Burton, DR, Koff, WC, Shapiro, L, Mascola, JR, Kwong, PD (2012) Somatic populations of PGT135-137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatics. Front Microbiol 3: pp. 315 CrossRef
    93. Huang, CC, Tang, M, Zhang, MY, Majeed, S, Montabana, E, Stanfield, RL, Dimitrov, DS, Korber, B, Sodroski, J, Wilson, IA, Wyatt, R, Kwong, PD (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: pp. 1025-1028 CrossRef
    94. Flynn, NM, Forthal, DN, Harro, CD, Judson, FN, Mayer, KH, Para, MF (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: pp. 654-665 CrossRef
    95. Raux, M, Finkielsztejn, L, Salmon-Ceron, D, Bouchez, H, Excler, JL, Dulioust, E, Grouin, JM, Sicard, D, Blondeau, C (2000) IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses 16: pp. 583-594 CrossRef
    96. Xu, W, Santini, PA, Sullivan, JS, He, B, Shan, M, Ball, SC, Dyer, WB, Ketas, TJ, Chadburn, A, Cohen-Gould, L, Knowles, DM, Chiu, A, Sanders, RW, Chen, K, Cerutti, A (2009) HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 10: pp. 1008-1017 CrossRef
    97. Mestecky, J, Wei, Q, Alexander, R, Raska, M, Novak, J, Moldoveanu, Z (2014) Humoral Immune Responses to HIV in the Mucosal Secretions and Sera of HIV-Infected Women. Am J Reprod Immunol 71: pp. 600-607 CrossRef
    98. Riedner, G, Hoffmann, O, Rusizoka, M, Mmbando, D, Maboko, L, Grosskurth, H, Todd, J, Hayes, R, Hoelscher, M (2006) Decline in sexually transmitted infection prevalence and HIV incidence in female barworkers attending prevention and care services in Mbeya Region, Tanzania. Aids 20: pp. 609-615 CrossRef
    99. Hoffmann, O, Zaba, B, Wolff, B, Sanga, E, Maboko, L, Mmbando, D, von Sonnenburg, F, Hoelscher, M (2004) Methodological lessons from a cohort study of high risk women in Tanzania. Sex Transm Infect 80: pp. ii69-ii73
    100. Mestecky, J, Wright, PF, Lopalco, L, Staats, HF, Kozlowski, PA, Moldoveanu, Z, Alexander, RC, Kulhavy, R, Pastori, C, Maboko, L, Riedner, G, Zhu, Y, Wrinn, T, Hoelscher, M (2011) Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses 27: pp. 469-486
    101. Raska, M, Elliott, MC, Hall, S, Czernekova, L, Zachova, K, Moldoveanu, Z, Brown, R, Mestecky, J, Novak, J HIV-1 gp120 glycosylation is cell type-specific and influences reactivity with HIV-1-specific antibodies. In: Rene, D, Jiri, H, Skalka, AM, Jan, S eds. (2010) Centennial Retrovirus Meeting: 29 Apr-04 May 2010; Prague. pp. 55-59
    102. Alexander, R, Mestecky, J (2007) Neutralizing antibodies in mucosal secretions: IgG or IgA?. Curr HIV Res 5: pp. 588-593 CrossRef
    103. Li, M, Gao, F, Mascola, JR, Stamatatos, L, Polonis, VR, Koutsoukos, M, Voss, G, Goepfert, P, Gilbert, P, Greene, KM, Bilska, M, Kothe, DL, Salazar-Gonzalez, JF, Wei, X, Decker, JM, Hahn, BH, Montefiori, DC (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: pp. 10108-10125 CrossRef
    104. Montefiori, DC (2009) Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 485: pp. 395-405 CrossRef
    105. Ochsenbauer, C, Kappes, JC (2009) New virologic reagents for neutralizing antibody assays. Curr Opin HIV AIDS 4: pp. 418-425 CrossRef
    106. Wei, X, Decker, JM, Liu, H, Zhang, Z, Arani, RB, Kilby, JM, Saag, MS, Wu, X, Shaw, GM, Kappes, JC (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: pp. 1896-1905 CrossRef
  • 刊物主题：Infectious Diseases; Virology;
  • 出版者：BioMed Central
  • ISSN：1742-6405
文摘
Background HIV-1 entry into host cells is mediated by interactions between the virus envelope glycoprotein (gp120/gp41) and host-cell receptors. N-glycans represent approximately 50% of the molecular mass of gp120 and serve as potential antigenic determinants and/or as a shield against immune recognition. We previously reported that N-glycosylation of recombinant gp120 varied, depending on the producer cells, and the glycosylation variability affected gp120 recognition by serum antibodies from persons infected with HIV-1 subtype B. However, the impact of gp120 differential glycosylation on recognition by broadly neutralizing monoclonal antibodies or by polyclonal antibodies of individuals infected with other HIV-1 subtypes is unknown. Methods Recombinant multimerizing gp120 antigens were expressed in different cells, HEK 293T, T-cell, rhabdomyosarcoma, hepatocellular carcinoma, and Chinese hamster ovary cell lines. Binding of broadly neutralizing monoclonal antibodies and polyclonal antibodies from sera of subtype A/C HIV-1-infected subjects with individual gp120 glycoforms was assessed by ELISA. In addition, immunodetection was performed using Western and dot blot assays. Recombinant gp120 glycoforms were tested for inhibition of infection of reporter cells by SF162 and YU.2 Env-pseudotyped R5 viruses. Results We demonstrated, using ELISA, that gp120 glycans sterically adjacent to the V3 loop only moderately contribute to differential recognition of a short apex motif GPGRA and GPGR by monoclonal antibodies F425 B4e8 and 447-52D, respectively. The binding of antibodies recognizing longer peptide motifs overlapping with GPGR epitope (268 D4, 257 D4, 19b) was significantly altered. Recognition of gp120 glycoforms by monoclonal antibodies specific for other than V3-loop epitopes was significantly affected by cell types used for gp120 expression. These epitopes included CD4-binding site (VRC03, VRC01, b12), discontinuous epitope involving V1/V2 loop with the associated glycans (PG9, PG16), and an epitope including V3-base-, N332 oligomannose-, and surrounding glycans-containing epitope (PGT 121). Moreover, the different gp120 glycoforms variably inhibited HIV-1 infection of reporter cells. Conclusion Our data support the hypothesis that the glycosylation machinery of different cells shapes gp120 glycosylation and, consequently, impacts envelope recognition by specific antibodies as well as the interaction of HIV-1 gp120 with cellular receptors. These findings underscore the importance of selection of appropriately glycosylated HIV-1 envelope as a vaccine antigen.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700